Immunovaccine Announces Withdrawal of Preliminary Prospectus

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES

Immunovaccine Inc. ("Immunovaccine" or the "Company") (TSX VENTURE:IMV)
announced today that, in light of current market conditions, it has determined
not to proceed with its previously announced overnight marketed public offering
of common shares at this time and is withdrawing its preliminary short form
prospectus previously filed on May 6, 2014. The Company does not intend, as
well, to move forward with the contemplated concurrent private placement of
common shares.


Albert Scardino, Executive Chairman of the Board of Directors of Immunovaccine
stated: "While there was interest from new investors and key current
shareholders indicated their continued support for the Company, the board of
directors considered that the proposed terms of the offering were not in the
best long-term interest of the Company. We sincerely appreciate the support of
our long-term shareholders."


About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease
vaccines based on the Company's DepoVax(TM) platform, a patented formulation
that provides controlled and prolonged exposure of antigens and adjuvants to the
immune system. Immunovaccine has advanced two T cell activation therapies for
cancer through Phase I human clinical trials. Lead cancer vaccine therapy,
DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian
cancer and glioblastoma (brain cancer). The Company is also advancing an
infectious disease pipeline including innovative vaccines for respiratory
syncytial virus (RSV) and anthrax.


Connect at www.imvaccine.com.

This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future, is forward-looking information.
Forward-looking statements are based on the estimates and opinions of management
on the date the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual results may differ
materially from those set forth in this press release due to risks affecting the
company, including access to capital, the successful completion of clinical
trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release except
as required by law.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine Inc.
Kimberly Stephens
Chief Financial Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Strategic Partners (media)
Tim Brons
(415) 675-7402
tbrons@vidasp.com

(TSXV:IMV)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024